Cultivate and expand the pillar industry of bio-economy

　　A few days ago, the "14th Five-Year Plan for Bioeconomic Development" (hereinafter referred to as the "Plan") was officially issued.

As my country's first five-year plan for bio-economy, the "Plan" proposes to accelerate the development of biotechnology and bio-industry, and make bio-economy a strong driving force for high-quality development. Information and other pillar industries.

What is the prospect of the pillar industries of the bio-economy, and how to cultivate and grow?

The reporter interviewed relevant enterprises and experts.

　　--editor

　　Develop bioenergy industry——

　　Make energy supply more green and low-carbon

　　Our reporter Ding Yiting

　　In early June, at the entrance of the Guoneng Linquan Biological Power Plant in Fuyang City, Anhui Province, trucks full of wheat straw lined up, waiting to be weighed and unloaded.

　　The straw on the stockyard is sent to the boiler to generate electricity through the conveyor belt.

"Take advantage of the wheat harvest season to reserve more raw materials. Recently, more than 120 vehicles of straw have been imported every day, and the average daily power generation can reach up to 1.4 million kilowatt-hours." The relevant person in charge of Guoneng Linquan Biological Power Plant said.

　　"Eat" into straw, "spit" out green electricity, is one of the important forms of bio-energy development and utilization.

Agricultural and forestry waste, livestock and poultry manure, domestic waste, waste oil... my country is rich in biomass resources and has great potential for energy utilization.

According to the "Plan", my country will actively develop bioenergy and build a biomass energy production and consumption system during the "14th Five-Year Plan" period.

"Biomass energy is the only renewable energy that can be converted into a variety of energy products. It can be used in various forms, including biomass power generation, biomass heating, biological natural gas, biomass briquette fuel, and biological liquid fuel." China Industrial Development Promotion Zhang Dayong, deputy secretary-general of the association and secretary-general of the Biomass Energy Industry Branch, said.

　　Industry experts generally believe that accelerating the development and utilization of biomass energy has obvious comprehensive benefits.

　　- Guarantee energy security.

In Hailun City, Heilongjiang Province, the SDIC Biotechnology Demonstration Project with an annual output of 30,000 tons of cellulosic ethanol is undergoing equipment debugging and process optimization, launching a sprint towards full production.

"The raw material of cellulosic ethanol is straw, so there is no need to worry about 'competing with others for grain'." Yue Guojun, an academician of the Chinese Academy of Engineering and chairman of SDIC Biotechnology Investment Co., Ltd., calculated an account: my country's annual output of straw is about 800 million tons , of which at least 100 million tons have not been effectively utilized. These 100 million tons of straw can produce 20 million tons of cellulosic ethanol, which is equivalent to gasoline extracted from about 100 million tons of crude oil.

If the transformation can be achieved, energy security will be more guaranteed.

　　——Promote pollution reduction and carbon reduction.

Yue Guojun introduced that using 20 million tons of cellulosic ethanol can reduce nearly 70 million tons of carbon dioxide emissions.

Not only that, the use of biofuels can also reduce emissions of particulate matter, hydrocarbons and other substances in vehicle exhaust.

Biomass energy can also play an important role in supporting circular agriculture and promoting ecological and environmental protection. For example, the organic fertilizer produced in the production of biological natural gas can effectively alleviate soil compaction.

　　- Helping rural revitalization.

The biomass energy industry has a wide coverage and a long industrial chain, which can drive the purchase, storage, processing, transportation, and application of rural biomass resources, and help farmers increase their income and become rich.

In Juancheng County, Shandong Province, the biomass power generation project invested by the Evergreen Group can utilize nearly 400,000 tons of agricultural and forestry waste each year, directly and indirectly driving more than 1,000 jobs and increasing the annual income of local people by 110 million yuan.

　　Compared with the rapid development of wind power and photovoltaic industries in recent years, the biomass energy industry with huge potential is still in its infancy, which is related to the high cost of raw material purchase and storage, the imperfect standard system, the need to improve the technical level, and the need to improve the policy support system.

　　"Wind and wind resources are free, but it costs money to buy straw raw materials. For agricultural and forestry biomass power generation projects, the fuel cost accounts for more than half of the production cost and is on the rise. Without special support policies, it is difficult for the project to continue to operate. "Introduced by the person in charge of a biomass power generation enterprise in Guangdong Province.

　　In response to this problem, the "Plan" also proposes a solution: increase financial investment and encourage local governments to establish and improve biomass energy financial subsidy policies.

Zhang Dayong called on relevant regions and departments to implement the requirements of the "Planning" and explore the establishment of a paid organic waste treatment mechanism as soon as possible, "who pollutes, who pays, who produces, who pays" and "who handles, who benefits".

　　There are also suggestions from enterprises to further innovate the business model of biomass resource acquisition and storage. For example, enterprises can provide farmers with services such as harvesting, transportation, and follow-up sowing to replace the cost of straw storage and storage, or use biomass energy to replace raw materials for farmers, thereby reducing resource acquisition and storage. cost.

　　"The development of bioenergy cannot be 'single action'. It must be integrated with other renewable energy, biochemical, biological agents and other industries, and take the path of comprehensive utilization of added value to continuously improve the comprehensive utilization efficiency of biomass resources." Zhang Dayong believes that, The "Plan" has released a positive signal to the biomass energy industry. It is hoped that the relevant departments will promote the implementation of the policy and speed up the construction of demonstration projects.

　　Develop the biopharmaceutical industry——

　　To better protect people's health

　　Our reporter Qiu Chaoyi

　　In Abu Dhabi, United Arab Emirates, the construction of a high-standard vaccine production base for cooperation between China and Afghanistan is intensifying. Dozens of technical backbones from Sinopharm Group China Biotechnology are here to provide technical support; Belgrade, Serbia, the first Chinese vaccine factory in Europe is officially put into operation, and can produce every year About 30 million doses of Sinopharm's new crown vaccine; Shanghai Jiading District, Sinopharm Group's China Biopharmaceutical Funuojian mRNA vaccine industrialization base will be completed in September, with a maximum annual output of 2 billion doses... The development and growth of Sinopharm Group's vaccine business is The epitome of the vigorous development of my country's biopharmaceutical industry.

　　The biopharmaceutical industry is a strategic emerging industry related to the national economy, people's livelihood and national security.

In recent years, especially since the prevention and control of the new crown pneumonia epidemic, the biopharmaceutical industry has entered a period of accelerated development.

According to data from the Ministry of Industry and Information Technology, the added value of my country's pharmaceutical industry increased by 23.1% year-on-year last year, which was 13.5 percentage points higher than the overall growth rate of all industries. The operating income exceeded 3.3 trillion yuan, a cumulative year-on-year increase of 18.7%, and the growth rate reached a new high in the past five years.

　　Not only the scale, but also the development quality of my country's biopharmaceutical industry is getting higher and higher——

　　The ability to innovate is stronger.

During the "13th Five-Year Plan" period, the R&D investment of pharmaceutical companies above designated size increased by about 8% annually; last year, the number of innovative drugs and innovative medical devices approved for marketing reached the highest level in the past five years; the number of innovative drugs currently under development ranks second in the world "The rapid growth of the talent team, the continuous increase of market investment, and the continuous optimization of the policy environment have promoted the emergence of a large number of innovative achievements. my country's biopharmaceutical industry is catching up quickly, shifting from imitation to innovation," said Yang Xiaoming, chief engineer of Sinopharm Group.

At present, regions such as the Beijing-Tianjin-Hebei region, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Economic Circle have become national bioeconomy innovation highlands. About 80% of the listed companies and 90% of the national first-class new drugs come from these regions.

　　The industrial system is more complete.

"China Bio-Company has formed an industrial system integrating 'science, industry, trade, industry, education and research'. From R&D, listing to marketing, the entire industry chain has been opened up." Zhang Yuntao, chief scientist of Sinopharm Group China Biotechnology, observed that in recent years, the company has been engaged in biomedical research for more than 30 years. The field of bioreactors, centrifuges and other equipment and chemical reagents at the front end of the supply chain is accelerating the realization of localized substitution, and the "stuck neck" link in the biomedical industry is decreasing.

　　greater international influence.

Liu Jingzhen, secretary of the party committee and chairman of Sinopharm Group, said that in recent years, a total of 4 biopharmaceutical varieties of Sinopharm Group have passed WHO pre-certification. The live attenuated polio vaccine has also entered the UNICEF procurement list, and a number of products such as the new crown nucleic acid detection kit have been certified by the European Union.

　　The vigorous development of the biopharmaceutical industry is inseparable from the strong support of relevant policies.

Focusing on drug research and development, the Ministry of Industry and Information Technology and other departments proposed to empower medical research and development with a new generation of information technology.

Focusing on the drug approval process, the State Food and Drug Administration has made great efforts to promote the inclusion of new drugs in priority review and approval, and formulated special approval procedures for innovative medical devices.

　　The "Planning" proposes to support the development of biomedicine for people's life and health in terms of market access, financial support, and talent development.

Since the beginning of this year, Shanghai, Fujian, Chongqing, Yunnan and other places have also successively issued several measures to promote the development of the biopharmaceutical industry.

　　Compared with the international advanced level, my country's biopharmaceutical industry still has shortcomings, and many fields are still in the follow-up stage.

"For example, the ability of new drug discovery and patent transformation is still weak, the accumulation of high-end instruments and reagents is insufficient, and the innovation ecological chain with enterprises as the main body, market-oriented, and deep integration of production, education and research still needs to be further improved," Zhang Yuntao said. The board can be solved through development. As long as we continue to improve the ability of industrial innovation, strengthen international exchanges and cooperation, and improve the security level of the industrial chain and supply chain, we are fully capable of becoming the "first phalanx" of the global biopharmaceutical industry.

　　In the long run, the biopharmaceutical market is broad and promising.

Liu Jingzhen said that during the "14th Five-Year Plan" period, Sinopharm Group will focus on the construction of national biosafety barriers, key core technologies, etc., comprehensively deploy innovative drugs, new biomedical materials, biological health care and other fields, and promote the high-quality development of the biopharmaceutical industry. Good service to people's health.

　　Develop bioinformatics industry——

　　Deep integration of biotechnology and information technology

　　Our reporter Han Xin

　　Information technology supports the development of new drugs, blockchain facilitates drug traceability, and big data supports telemedicine. Today, a new generation of information technology is rapidly being applied to the biomedical industry.

　　In Haidian District, Beijing, in the laboratory of Huashen Zhiyao Biotechnology Co., Ltd., computer software is running at high speed. Through simulation screening of a series of candidate compounds, the relationship between drugs and diseases is found, and the development of an antibody drug is accelerated.

　　"The research and development of a drug can usually be divided into two stages: drug discovery and clinical research. The success of drug discovery depends on whether the new drug can be finally launched." Peng Jian, founder of Huashen Zhiyao, said that traditional drug discovery requires Relying on manual screening among thousands of compounds is slow and has a low success rate; now, by applying artificial intelligence technology, drug candidates can be virtually screened, helping researchers quickly find the best analog compounds, thereby significantly improving the potential of drugs. Screening efficiency and success rate.

　　Industry insiders often say that the traditional pharmaceutical industry has high costs, high investment and high risks.

The emergence of artificial intelligence is expected to solve these problems.

"Since its establishment more than a year ago, we have built a new generation of macromolecular structure modeling and computing platform driven by deep learning, and received orders for antibody drug development from some multinational pharmaceutical companies." Peng Jian said that he hopes to use artificial intelligence technology to accelerate new drug research and development , and develop drugs on targets that were difficult to make drugs in the past, so as to better expand the development space of artificial intelligence pharmaceuticals.

　　In addition to the pharmaceutical field, information technology is also blossoming in the fields of drug distribution and health management.

　　Open the "Gaoji Internet Hospital" applet, find a professional doctor online for consultation and refill, and then purchase medicines online and pay for medical insurance. Within half an hour, a staff member will take orders, sort, pack boxes, and deliver medicines to your door.

　　"Since 2020, with the increasing willingness and demand for online medical treatment, the company has accelerated the pace of digital transformation." Li Bo, CEO of Gaoji Medical, introduced that connecting patients, hospitals and pharmaceutical companies more efficiently through the Internet can Provide users with whole-life-cycle health management services such as preventive early screening, intelligent consultation, online diagnosis and treatment, and health testing, which can not only effectively alleviate the problems of patients in remote areas seeing a doctor and taking medication, but also create new growth points for enterprises. From 2019 to present , the company's revenue nearly doubled.

　　JD Health has established a medical imaging service platform to realize the interconnection of medical data between regions; Ali Health has developed a drug traceability code to help companies manage more accurate drugs and make patients more assured... Research institute data shows that in recent years, my country's Internet medical industry scale Maintain a high growth trend with a compound annual growth rate of more than 30%, and it is expected to further improve in the future.

　　According to the "Plan", my country will speed up information technology to empower the bioinformatics industry.

The specific contents include: relying on artificial intelligence technology, biomedicine and health big data resources, develop intelligent decision-making knowledge models and algorithms, and assist in the research and development of personalized new drugs; use 5G, blockchain, Internet of Things and other cutting-edge technologies to realize the production of drugs and vaccines. To use full life cycle management; to deepen the application of health big data in medical research, education and training, clinical diagnosis and treatment, product development, industry governance, medical insurance payment, etc.

　　The bioinformatics industry has broad prospects, is in a period of rapid growth, and still faces some problems.

　　"Artificial intelligence requires deep learning in a large amount of data, and my country's innovative drug research and development started late. The accumulation of raw data is limited and the storage is scattered, which limits the development of artificial intelligence pharmaceuticals to a certain extent." In Peng Jian's view, my country With a large population base, it is easy to form massive medical data. With the continuous improvement of the data system and the continuous enhancement of computing power, as long as the systematic training of interdisciplinary talents is continuously strengthened, it is very likely to achieve catch-up.

　　The relevant person in charge of Hillhouse Investment said that to develop and expand the bioinformatics industry, it is necessary to continuously form key innovations in basic life science theories, high-end instruments and reagents, and continue to accumulate relevant technologies.

　　"The development and growth of Internet medical care depends on the active participation of more public hospitals." Li Bo suggested that supporting policies should be introduced to encourage experts from public medical institutions to practice online at multiple sites, improve the supervision system for doctors' practice, and better optimize the allocation of medical resources. High-quality medical services benefit more people.